ArQule, Inc. (NASDAQ: ARQL) Starts Presentation at 30th Annual ROTH Conference
ArQule (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The company’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need to significantly extend and improve the lives of patients. The company’s clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations. The company’s proprietary pipeline includes Derazantinib, Miransertib (ARQ 092), ARQ 751 and ARQ 761. Additionally, ArQule has advanced ARQ 531 to phase 1 for patients with B-cell malignancies refractory to other therapeutic…







